Vaccine, diphtheria and tetanus toxoid

Generic Medicine Info
Indications and Dosage
Active immunisation against tetanus and diphtheria
Adult: Primary immunisation: 2 doses of 0.5 mL each, given at 4 weeks interval; 3rd (reinforcing) dose to be given after 6-12 months. Booster dose: 0.5 mL every 10 years.
Child: Primary immunisation: 6 weeks to ≤6 years 3 doses of 0.5 mL each, given at 4-8 weeks intervals or at 2, 4, 6 months of age; 4th dose to be given 6 months after the 3rd dose or at approx 15-18 months of age; 5th dose given at 4-6 years of age. Booster dose may be given based on national recommendations and should begin 10 years after the last dose of the primary immunisation series. ≥7 years Same as adult dose.
Special Patient Group
Immunocompromised patient: Administer inactivated vaccines ≥2 weeks prior to initiation of immunosuppressive therapy.
History of hypersensitivity reactions or severe local reactions (Arthus-type) to previous vaccination with diphtheria or tetanus. Moderate or severe acute illness with or without fever.
Special Precautions
Patient with coagulation/bleeding disorders (including thrombocytopaenia), Guillain-Barré syndrome within 6 weeks prior to receiving vaccination. Severely immunocompromised patients. Children. Pregnancy and lactation. Not intended for the treatment of diphtheria or tetanus infections.
Adverse Reactions
Significant: Anaphylactoid/hypersensitivity reactions, syncope.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea.
General disorders and administration site conditions: Inj site reactions (e.g. pain, redness, bruising, swelling); fever, headache, asthenia, fatigue.
Metabolism and nutrition disorders: Loss of appetite.
Musculoskeletal and connective tissue disorders: Myalgia, arthralgia.
Nervous system disorders: Dizziness.
Skin and subcutaneous tissue disorders: Rash, pruritus.
Monitoring Parameters
Monitor for hypersensitivity reactions, 15 minutes after administration.
Drug Interactions
Increased risk of bleeding with anticoagulants. Decreased therapeutic effect and immune response with immunosuppressive therapies (e.g. high dose corticosteroids).
Description: Diphtheria and tetanus toxoid vaccine promotes active immunity by inducing specific production of antibodies that protect against the diseases caused by exposure to C. diphtheriae and C. tetani.
Duration: Immunity: Up to 10 years.
Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance with local requirements.
ATC Classification
J07AM51 - tetanus toxoid, combinations with diphtheria toxoid ; Belongs to the class of tetanus bacterial vaccines.
Anon. Diphtheria and Tetanus Toxoids. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 16/07/2018.

Anon. Diphtheria and Tetanus Toxoids. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 16/07/2018.

Buckingham R (ed). Diphtheria and Tetanus Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 16/07/2018.

Diphtheria and Tetanus Toxoids Adsorbed (Sanofi Pasteur Limited). DailyMed. Source: U.S. National Library of Medicine. Accessed 16/07/2018.

Disclaimer: This information is independently developed by MIMS based on Vaccine, diphtheria and tetanus toxoid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in